France will become the first country in the European Union to reimburse anti-obesity drugs through its public healthcare system, Health Minister Stéphanie Rist announced on Thursday (28 May).
From mid-June, severely obese patients in France will be able to receive partial or full reimbursement for weight-loss injections Wegovy and Mounjaro under the national social security system.
The move marks a major shift in access to obesity treatment in Europe, where the high cost of the drugs has remained a barrier for many patients.
“We are the first country in the European Union to provide reimbursement for patients who need it, under general law, on a permanent basis,” Rist said during an interview with TF1 television.
The treatment will be available to adults with severe obesity who meet strict medical criteria.
Patients with a body mass index (BMI) of at least 35 and at least one obesity-related illness will qualify. Those with a BMI of 40 or above will also be eligible, even without additional health conditions.
The drugs will officially be reimbursed at a rate of 65%. However, Rist said most eligible patients are likely to receive full coverage because many already qualify for 100% reimbursement due to related medical conditions.
“The target population is around one million people. However, this does not mean that everyone will receive the treatment, as it always depends on the individual case and the doctor’s prescription,” she said.
Wegovy, produced by Danish pharmaceutical company Novo Nordisk, and Eli Lilly’s Mounjaro have become some of the world’s most sought-after obesity treatments in recent years.
The drugs help patients lose weight by regulating appetite and blood sugar levels. Demand has surged globally as governments and healthcare systems seek ways to tackle rising obesity rates.
In France, the treatments have been available by prescription since 2024, but patients have until now had to cover the cost themselves. Monthly treatment costs average around €300.
Rist estimated the reimbursement programme would eventually cost the French state around €100 million per year as prescriptions increase.
Last year, France also widened access by allowing all doctors, not just specialists such as endocrinologists, to prescribe the treatments.
According to a French study published in 2024, around 18% of France’s population - roughly 10 million people - are obese.
As of January this year, more than 70,000 patients in France were already being treated with Mounjaro, according to estimates.
Health officials said the reimbursement programme is intended to help patients suffering from chronic obesity-related conditions rather than support cosmetic weight loss.
“It addresses a growing public health challenge and the urgency of appropriate therapeutic care,” said Étienne Tichit, General Manager of Novo Nordisk France.
Mike Doustdar, president and chief executive of Novo Nordisk, said the decision showed “the foresight and maturity of the French system.”
The decision comes as competition in the obesity drug market continues to intensify.
Novo Nordisk and Eli Lilly have both launched oral versions of their weight-loss treatments in the U.S. Last week, the European Medicines Agency recommended approval of Novo Nordisk’s Wegovy pill, which could become the first oral anti-obesity drug available in Europe.
In the UK, weight-loss drugs including Wegovy and Mounjaro are available on the NHS, but access remains limited under strict eligibility criteria. Patients typically need to meet BMI thresholds and have obesity-related health conditions.
Ukrainian President Volodymyr Zelenskyy said that Ukraine was carrying out tests on a new weapon to intercept dron...
European Commission President Ursula von der Leyen is outlining the EU's priorities in her annual State of the Union address, covering security...
At least 12 Palestinians, including five children, were killed after a seven-storey apartment building in Gaza collapsed overnight, leaving dozens ...
U.S. Central Command said 101 commercial vessels have been redirected in the Strait of Hormuz, while oil prices rose more than three per cent amid fresh regional attacks and supply concerns.
U.S. President Donald Trump has again said Iran is keen to reach a deal quickly, but a senior Iranian security official rejected the claim, saying Tehran will not negotiate until its conditions are met.
A Russian strike on a farm warehouse in Pryluky, north-central Ukraine, has killed at least three people, local police said. Meanwhile, EU foreign policy chief Kaja Kallas said an attack on a train near the Polish border was an attempt to intimidate Ukraine's allies.
A Danish military helicopter came within “metres” of being struck by flares fired by a Russian warship, Denmark's Defence Minister Jeppe Bruus said on Tuesday. Russia accused Denmark of carrying out “dangerous manoeuvres” near its ship, and said it was investigating the incident.
European Commission President Ursula von der Leyen is outlining the EU's priorities in her annual State of the Union address, covering security, support for Ukraine, trade with China, migration, climate and artificial intelligence.
Ukrainian President Volodymyr Zelenskyy said that Ukraine was carrying out tests on a new weapon to intercept drones and had recorded a successful hit overnight.
European Commission President Ursula von der Leyen is outlining the EU's priorities in her annual State of the Union address, covering security, support for Ukraine, trade with China, migration, climate and artificial intelligence.
Wednesday's session of the 24th Arab Media Summit in Dubai has shifted the discussion towards a central question for modern media: how can regional news organisations tell their own stories while reaching audiences far beyond their borders?
Here's your AnewZ Daily Brief for 16 September 2026. These are the top five stories making headlines in the field of artificial intelligence (AI).
Russia will hold parliamentary elections from 18 to 20 September 2026, the country's first State Duma vote since Moscow launched its full-scale invasion of Ukraine in February 2022.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment